Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
11%
Afatinib
10%
Alectinib
7%
Anaplastic Lymphoma Kinase
11%
Anaplastic Lymphoma Kinase Inhibitor
5%
Biological Marker
11%
Chemoradiation Therapy
5%
Chemotherapy
12%
Circulating Tumor DNA
5%
Cohort Study
8%
Combination Therapy
5%
Crizotinib
12%
Disease
13%
Epidermal Growth Factor Receptor
55%
Erlotinib
7%
Immunotherapy
6%
Lung Cancer
37%
Malignant Neoplasm
7%
Neoplasm
30%
Non Small Cell Lung Cancer
100%
Osimertinib
21%
Overall Survival
20%
Palbociclib
5%
Progression Free Survival
16%
Protein Tyrosine Kinase Inhibitor
21%
Randomized Controlled Trial
5%
Medicine and Dentistry
Adverse Event
11%
ALK Inhibitor
5%
Anaplastic Lymphoma Kinase
8%
Biological Marker
12%
Biopsy
7%
Chemoradiotherapy
5%
Crizotinib
10%
Disease
7%
Durvalumab
5%
Epidermal Growth Factor Receptor
39%
Exon
23%
Hazard Ratio
5%
Immunotherapy
8%
Lorlatinib
7%
Lung Cancer
24%
Lung Nodule
5%
Malignant Neoplasm
9%
Metastatic Carcinoma
5%
Molecular Imaging
5%
Neoplasm
30%
Non Small Cell Lung Cancer
80%
Non-Small Cell Lung Cancer
8%
Osimertinib
11%
Overall Survival
13%
Palbociclib
5%
Progression Free Survival
11%
Radiation Therapy
5%
Resistance Mutation
8%
Targeted Therapy
16%
Tyrosine-Kinase Inhibitor
13%
Keyphrases
Adverse Events
5%
Atezolizumab
5%
Biomarker Testing
8%
EGFR mutation
7%
Epidermal Growth Factor Receptor
10%
Exon 20
7%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
14%
Molecular Tumor Board
7%
Mutational Profile
5%
Netherlands
6%
Non-small Cell Lung Cancer (NSCLC)
25%
Non-small Cell Lung Cancer Patients
6%
Overall Survival
6%
Predictive Biomarker
9%
Targeted Therapy
8%
